Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Revenue for Q3 FY25 stood at Rs. Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year. - Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years. - Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand. - ARPOB is increasing (Rs 61,750 in Q3 FY25 vs.
From Jupiter Life Line Hospitals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue for Q3 FY25 stood at Rs. 322 crores, a 17.7% YoY increase; 9-month revenue was Rs. 934.8 crores, up 19.5% YoY.
- Volume increased from 651,500 to 727,500 in 9 months.
- Occupancy improved to 66.7% from 63.2% YoY.
- ARPOB (Average Revenue Per Occupied Bed) increased to Rs. 59,100 from Rs. 53,600 YoY.
- Expansion via three new hospitals (Dombivli 500 beds by Q1 FY27, Pune 500 beds by 2028, Mira Road 300 beds by 2029) aims to increase bed capacity to ~2,500.
- Industry norm suggests new hospitals will be EBITDA negative in year 1, breakeven in year 2, and positive in year 3.
2 more points from Jupiter Life Line Hospitals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Jupiter Life Line Hospitals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX for FY25 (9 months) excluding recent land acquisition is around Rs. 100 crores, mainly for Dombivli and Indore projects.
- Total planned CAPEX for three new hospitals (Dombivli, Pune 2 at Bibvewadi, Mira Road) is approximately Rs. 1,400 crores.
- Land acquisition in Mira Road for around Rs. 75 crores, fully funded through internal accruals and equity reserves.
- Mira Road hospital planned as a 300-bed full-service multi-specialty hospital with an estimated total CAPEX of Rs. 400 crores (including land).
- Dombivli hospital expected operational by Q1 FY27 with staggered investment.
2 more points from Jupiter Life Line Hospitals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jupiter Life Line Hospitals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jupiter Life Line Hospitals has a pipeline of three new hospitals in addition to the existing three operational ones.
- New hospitals planned:
- Dombivli: 500 beds, expected operational by Q1 FY27.
- Pune 2 (Bibvewadi): 500 beds, expected operational in calendar year 2028.
- Mira Road: 300 beds, expected operational in calendar year 2029.
- Total bed capacity after new hospitals will be approximately 2,500 beds.
- Estimated CAPEX for these three hospitals is around Rs. 1,400 crores.
- Recent land acquisition in Mira Road was for Rs. 75 crores, part of the Rs. 400 crore estimated CAPEX for that hospital.
2 more points from Jupiter Life Line Hospitals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Jupiter Life Line Hospitals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹388 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jupiter Life Line Hospitals Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Jupiter Life Line Hospitals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jupiter Life Line Hospitals Ltd Q3 FY25 results?
Revenue for Q3 FY25 stood at Rs. Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year. - Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years. - Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand. - ARPOB is increasing (Rs 61,750 in Q3 FY25 vs.
What is Jupiter Life Line Hospitals Ltd share price analysis?
Jupiter Life Line Hospitals Ltd currently shows a neutral. The stock trades at a P/E of 54.1 with a market cap of ₹10,351 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jupiter Life Line Hospitals Ltd planning capital expenditure?
Current CAPEX for FY25 (9 months) excluding recent land acquisition is around Rs.
Keep Jupiter Life Line Hospitals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.